This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...

Intellia Therapeutics' most advanced product candidates, NTL-2002 and Next-z, are aimed as in vivo gene therapies, using Crispr/Cas9 encapsulated in their proprietary LNP, which after being ...

It's clear though that these companies need time. Even with the only approved CAS9 based treatment out there, CRISPR is still years away from achieving its potential. In a recent update to ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on the ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

WASHINGTON — Former Trump administration health policy aide Abe Sutton is incoming President Trump’s likely pick to lead the Center for Medicare and Medicaid Innovation, two sources familiar ...

ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China ...

China-born biologist Zhang Feng has been awarded the United States ... work developing the revolutionary gene-editing tool CRISPR-Cas9. According to the citation from the US Patent and Trademark ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...